BACKGROUND: At present, therapy of children with chronic hepatitis B and C is still based on few drugs, all burdened by a series of side-effects, unsatisfactory serum conversion rates, and/or drug-resistance. Moreover, selection of subjects to treat with conventional therapies is not univocal, especially during the pediatric age when the disease course is often mild with significant spontaneous seroconversion rate. Our review deals with pros and cons points when a physician decides to design a drug therapy for a child with chronic viral hepatitis, and different possible therapeutic opportunities. METHODS: A literature search was performed through PubMed. The newest articles, reviews, systematic reviews, and guidelines were included in this review. RESULTS: The management of children with viral hepatitis is still controversial over whom and when to treat and the use of drug(s). Novel therapeutic strategies have been evaluated only in clinical and preclinical trials involving, for instance, "therapeutic" vaccines. The data on safety and effectiveness of new drugs are also reviewed. CONCLUSION: The results of reported studies confirmed that at least some of the new drugs, with greater efficacy and/or minor side-effects, will be used clinically.
BACKGROUND: At present, therapy of children with chronic hepatitis B and C is still based on few drugs, all burdened by a series of side-effects, unsatisfactory serum conversion rates, and/or drug-resistance. Moreover, selection of subjects to treat with conventional therapies is not univocal, especially during the pediatric age when the disease course is often mild with significant spontaneous seroconversion rate. Our review deals with pros and cons points when a physician decides to design a drug therapy for a child with chronic viral hepatitis, and different possible therapeutic opportunities. METHODS: A literature search was performed through PubMed. The newest articles, reviews, systematic reviews, and guidelines were included in this review. RESULTS: The management of children with viral hepatitis is still controversial over whom and when to treat and the use of drug(s). Novel therapeutic strategies have been evaluated only in clinical and preclinical trials involving, for instance, "therapeutic" vaccines. The data on safety and effectiveness of new drugs are also reviewed. CONCLUSION: The results of reported studies confirmed that at least some of the new drugs, with greater efficacy and/or minor side-effects, will be used clinically.
Authors: Si-Nafa Si-Ahmed; Pierre Pradat; Roeland Zoutendijk; Maria Buti; Vincent Mallet; Claire Cruiziat; Katja Deterding; Jérôme Dumortier; François Bailly; Rafael Esteban; Heiner Wedemeyer; Harry L Janssen; Fabien Zoulim Journal: Antiviral Res Date: 2011-07-13 Impact factor: 5.970
Authors: Cara L Mack; Regino P Gonzalez-Peralta; Nitika Gupta; Daniel Leung; Michael R Narkewicz; Eve A Roberts; Philip Rosenthal; Kathleen B Schwarz Journal: J Pediatr Gastroenterol Nutr Date: 2012-06 Impact factor: 2.839
Authors: Etienne M Sokal; Deirdre A Kelly; Jacek Mizerski; Isabel B Badia; Jorge A Areias; Kathleen B Schwarz; Angela Vegnente; Nancy R Little; Stephen D Gardener; Maureen M Jonas Journal: Hepatology Date: 2006-02 Impact factor: 17.425
Authors: Z Han; Y Shi; J Zhu; Y Chen; F Yin; L Xia; G Luo; Z Gao; J Liu; G Jia; C Li; X Zhou; Y Han Journal: J Viral Hepat Date: 2013-04 Impact factor: 3.728
Authors: Kyung Jae Lee; Byung Ho Choe; Jae Young Choe; Ju Young Kim; In Sook Jeong; Ju Whi Kim; Hye Ran Yang; Ju Yuong Chang; Kyung Mo Kim; Jin Soo Moon; Jae Sung Ko Journal: J Korean Med Sci Date: 2018-02-19 Impact factor: 2.153
Authors: Martina Penazzato; Devasena Gnanashanmugam; Pablo Rojo; Marc Lallemant; Linda L Lewis; Francesca Rocchi; Agnes Saint Raymond; Nathan Ford; Rohan Hazra; Carlo Giaquinto; Yodit Belew; Diana M Gibb; Elaine J Abrams Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079